NBQX disodium salt
Cat. No. 1044
Chemical Name: 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt
Biological ActivityPotent, selective and competitive AMPA receptor antagonist. Neuroprotective and anticonvulsant; active in vivo. More water soluble disodium salt of NBQX (Cat. No. 0373). Also available as part of the AMPA Receptor Tocriset™.
Licensing InformationSold with the permission of Novo Nordisk A/S
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Gill et al (1992) The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX) in a rat focal ischaemia model. Brain Res. 580 35. PMID: 1504814.
Zeman and Lodg (1992) Pharmacological characterization of non-NMDA subtypes of glutamate receptors in the neonatal rat hemisected spinal cord in vitro. Br.J.Pharmacol. 106 367. PMID: 1382781.
Sheardown et al (1993) The pharmacology of AMPA receptors and their antagonists. Stroke 24 146. PMID: 7504337.
Namba et al (1994) Antiepileptogenic and anticonvulsant effects of NBQX, a selective AMPA receptor antagonist, in the rat kindling model of epilepsy. Brain Res. 638 36. PMID: 8199874.
If you know of a relevant citation for this product please let us know.
Keywords: NBQX disodium salt, supplier, water, soluble, NBQX, Glutamate, AMPA, Receptors, iGlu, Ionotropic, antagonists
Find multiple products by catalog number
New Products in this Area
Non-competitive AMPA/kainate antagonistQNZ 46
NR2C/NR2D-selective NMDA receptor non-competitive antagonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.